85826-33-1

Basic information

• Product Name: 5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE
• Synonyms: 5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE
• CAS NO: 85826-33-1
• Molecular Formula: C₈H₈Cl₂N₂
• Molecular Weight: 203.07
• Mol File: 85826-33-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 261°C at 760 mmHg
• Flash Point: 136.9°C
• Appearance: /
• Density: 1.265g/cm³
• Vapor Pressure: 0.0193mmHg at 25°C
• Refractive Index: 1.547
• CAS DataBase Reference: 5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE(85826-33-1)
• EPA Substance Registry System: 5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE(85826-33-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 85826-33-1(Hazardous Substances Data)

Usage

Description

5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE is a pyrimidine derivative characterized by the presence of an allyl group, two chlorine atoms, and a methyl group attached to a pyrimidine ring. It has potential applications in organic chemistry and pharmaceuticals due to its unique structure and reactivity.

Uses

Used in Organic Chemistry:
5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE is used as a building block in the synthesis of various organic compounds, contributing to the development of new chemical entities.
Used in Pharmaceutical Industry:
5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE is used as a potential candidate for drug development, due to its unique structure and reactivity that may exhibit biological activity beneficial for medicinal applications.

InChI:InChI=1/C8H8Cl2N2/c1-3-4-6-7(9)11-5(2)12-8(6)10/h3H,1,4H2,2H3

Upstream product

• 85826-32-0 5-Allyl-2-methyl-4,6-dihydroxypyrimidine 
• 85826-32-0 6-hydroxy-2-methyl-5-(2-proren-1-yl)-4(1H)-pyrimidinone 
• 2049-80-1 (2-propenyl)propanedioic acid diethyl ester 
• 124-42-5 acetamidine hydrochloride 

Downstream Products

• 85826-34-2 5-Allyl-4-amino-2-methyl-6-chloropyrimidine 
• 85826-35-3 (5-Allyl-6-chloro-2-methyl-pyrimidin-4-yl)-methyl-amine 
• 1001397-56-3 1-methylethyl 4-({7-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)-1-piperidinecarboxylate 
• 1001397-53-0 1,1-dimethylethyl 4-({7-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)-1-piperidinecarboxylate 
• 1001397-52-9 4-chloro-7-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine 
• 1001397-48-3 6-chloro-N-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methyl-5-(2-propen-1-yl)-4-pyrimidinamine 
• 85826-41-1 Benzyl-[6-chloro-5-(2,3-dibromo-propyl)-2-methyl-pyrimidin-4-yl]-amine 
• 85826-40-0 2-[6-Chloro-5-(2,3-dibromo-propyl)-2-methyl-pyrimidin-4-ylamino]-ethanol 
• 85826-39-7 [6-Chloro-5-(2,3-dibromo-propyl)-2-methyl-pyrimidin-4-yl]-methyl-amine 
• 85826-38-6 4-Amino-5-(2',3'-dibromo-1'-propyl)-2-methyl-6-chloropyrimidine 
• 644994-58-1 allyl-[5-bromo-7-(2,4-dichloro-phenyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-cyclohexyl-amine 
• 268547-66-6 N-Allyl-3-bromo-1-(2,4-dichlorophenyl)-4-(4-heptyl)amino-6-methyl-5,7-diazaindole 
• 268547-65-5 3-Bromo-1-(2,4-dichlorophenyl)-4-(4-heptylamino)-6-methyl-5,7-diazaindole 
• 644994-57-0 allyl-[5-bromo-7-(2,4-dichloro-phenyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-methyl-amine 

Relevant articles and documents

Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available g protein-coupled receptor 119 agonists

GPR119 is a 7-transmembrane receptor that is expressed in the enteroendocrine cells in the intestine and in the islets of Langerhans in the pancreas. Indolines and 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines were discovered as G protein-coupled receptor 119

Synthesis of pyrrolopyrimidine CRF-R1 antagonists containing a tricyclic core via an intramolecular heck reaction

A synthetic route to pharmaceutically important tricyclic pyrrolopyrimidines was developed. The method employs a palladium-mediated Heck cyclization as the critical step in the construction of the final six membered ring.

CRF receptor antagonists and methods relating thereto

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, m, A, B, C, R, R1, R2and Ar are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same